This project aims to develop transdermal microneedle formulations for delivering biologic drugs over several weeks or months. Biologics (e.g. peptides, DNA, RNA) are emerging drugs for challenging diseases, including cancers and Alzheimer’s disease. Due to their macromolecular size, these drugs cannot be absorbed orally. Thus, they have traditionally required frequent invasive injections.
To overcome this issue, we have developed a novel material that can be used as a pharmaceutical excipient to greatly increase the drug loading capacity and drug release duration. It is suitable for formulating different dosage forms including oral, transdermal and implantable formulations. Using this technology, we have previously demonstrated extended drug release of a small-molecule drug over 2 months from a transdermal microneedle patch. This project will extend the application of the microneedle patch to delivering biologics. Several options are available with regard to the therapeutic agent and target disease. These are to be agreed with the supervisor team.
The clinical translation of this ultra-long-acting microneedle technology will empower patients to manage demanding medication regimens themselves. Not only will the microneedle patch replace invasive injections with a painless alternative that patients can self-administer, but it will also significantly reduce the frequency at which the patients will need to take their biologic medications. It will provide a set-and-forget way for patients to self-medicate.
You will join a friendly, diverse and multidisciplinary team spanning the School of Pharmacy and the School of Engineering. You will work collaboratively with our clinical and industry partners and have access to state-of-the-art research facilities across the university. You will develop skills in material science, formulation design, microfabrication, pharmaceutical analysis and toxicology testing, among others. There may also be opportunities to partake in patient engagement and commercialisation activities relating to bringing the technology to market.
You should hold or expect to hold a 2:1 or 1st class degree in a biomedical or pharmaceutical science or equivalent subject. A Masters degree or prior research experience would be advantageous.
Continue with Facebook
